All Updates

All Updates

icon
Filter
M&A
Context Therapeutics acquires CT-95 for solid tumor treatment from Link Immunotherapeutics
Precision Medicine
Jul 10, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jul 10, 2024

Context Therapeutics acquires CT-95 for solid tumor treatment from Link Immunotherapeutics

M&A

  • Context Therapeutics has acquired CT-95, a bispecific antibody drug previously owned by Link Immunotherapeutics, for an undisclosed amount.

  • CT-95, now added to Context Therapeutics' portfolio, is a potentially first-in-class mesothelin x CD3 T cell-engaging bispecific antibody. It has received Investigational New Drug (IND) clearance from the FDA and is claimed to have high potential in treating several underserved solid cancers, including ovarian, lung, and pancreatic. Following the acquisition, Context Therapeutics plans to begin clinical trials for the drug, which, along with the acquisition, are planned to be funded using its existing cash reserves.

  • Context Therapeutics is a biopharmaceutical company that develops novel treatments for solid tumors. The company's primary focus is on CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target CLDN6-positive tumors. Such tumors include ovarian, endometrial, testicular, and lung cancers, where CLDN6 is present in high concentrations but is minimally expressed in healthy adult tissues​. The company aims to advance CTIM-76 through to clinical development, with a Phase I clinical trial expected to begin in mid-2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.